## Seizure Prophylaxis Neurocritical Care

The following are evidence-based recommendations for the use of seizure prophylaxis in neurocritical care patients.

<style type="text/css">
.tg  {border-collapse:collapse;border-spacing:0;}
.tg td{font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;}
.tg th{font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;}
</style>
<table class="tg">
  <tr>
    <th class="tg-031e">PATIENT POPULATION</th>
    <th class="tg-031e">PROPHYLACTIC MEDICATION</th>
    <th class="tg-031e">DURATION</th>
  </tr>
  <tr>
    <td class="tg-031e">Severe Traumatic Brain Injury (GCS &lt; 8)</td>
    <td class="tg-031e" rowspan="2">Levetiracetam 1000 mg IVPB x1 dose then 500<br>mg IVPB or enteral Q8hrs<br><br>Alternative: Phenytoin or fosphenytoin 20 mg/kg<br>IVPB x1 dose then phenytoin 5 mg/kg/day in 2<br>divided doses IVPB or enteral</td>
    <td class="tg-031e" rowspan="2">7 Days</td>
  </tr>
  <tr>
    <td class="tg-031e">SAH</td>
  </tr>
</table>

- For a patient who has an EEG confirmed seizure, recommend changing levetiracetam to 1500 mg IVPB x1 then 1000 mg IVPB or enteral Q8hrs.

Guidelines do not support the use of prophylactic anti-epileptics in patients with ICH. In addition, practice parameter recommendations do not support
the use of prophylactic anti-epileptics in patients with brain tumors.

Risk factors for development of early seizures in traumatic brain injury:

- GCS<10(or<8)
- Cortical contusion
- Depressed skull fracture
- SDH, epidural and ICH
- Penetrating head wound
- Seizure within 24 hours of injury

Risk factors for development of early seizures in aSAH:
- Aneurysm in the MCA
- Associated ICH
- Rebleeding
- Infarction
- Poor neurologic grade or Hunt and Hess grade > 3

References:

- Bratton SL, et al. Antiseizure prophylaxis. <i>J of Neurotrauma</i> 2007;24:S83-S86.
- Connolly ES, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. <i>Stroke</i> 2012; 43:1711-1737.
- Fuller KL, et al. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. <i>Epilepsia</i> 2013;54(1):45-57.
- Glantz MJ, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neurology</i> 2000; 54:1886
- Inaba K, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. <i>J Trauma Acute Care Surg</i> 2013;74(3):766-773.
- Jones KE, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. <i>Neurosurg Focus</i> 2008;25(4):1-5.
- Kruer RM, et al. Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam. <i>J of Crit Care</i> 2013.Published ahead of print.
- Milligan TA, et al. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71:665-669. Morgenstem LB, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. <i>Stroke</i> 2010;41:2108-2129.
- Rhoney DH, et al. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology 2000;55:258-265. Sirven JI, et al. Seizure prophylaxis in patients with brain tumors: A meta-analysis. <i>Mayo Clin Proc</i> 2004; 79:1489-1494.
- Spencer DD, et al. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. <i>Pharmacotherapy</i> 2011;31(10):934-941.
- Szaflarski JP, et al. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam verus phenytoin for seizure prophylaxis. <i>Neurocrit Care</i> 2010; 12:165-172.
- Temkin NR, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. <i>N Engl J Med</i>. 1990;323:497-502.